Advancing Precision Medicine by Simplifying Complex Pathology

Our proprietary technology and integrated team approach enables a clearer path toward FDA approval.

Quantitative Tissue Analysis for Precision Medicine

Flagship Biosciences speeds drug approval by applying our technology and scientific strategy to pathology-based precision medicine. Our focus is on quantitative, in situ biomarker approaches for targeted therapies and immuno-oncology.
Our Solutions

Fit-for-Purpose Quantitative Endpoints

Flagship’s proprietary technology and scientific team enable success for your drug facing even the toughest tissue interpretation challenges. We create fit-for-purpose in situ assays and calibrated quantitative endpoints based on our proprietary tissue image analysis tools. We support your clinical trial exploratory studies and patient selection strategies in our in-house research and CLIA laboratories. The proven precision endpoints are then integrated into a companion diagnostic which supports your drug through our FDA Quality Manufacturing System.

Drug Development

TARGETED THERAPIES

Flagship adapts to client needs using advanced proprietary image analysis tools and multiple immunohistochemistry platforms to bring the best solution to your tissue challenge.

IMMUNO-ONCOLOGY

Flagship’s approaches empower researchers and clinicians to interpret and understand complex biological endpoints within the tissue context.

Companion Diagnostics

CLINICAL TRIALS

Flagship's clinical trial and regulatory experience is critical for successful quantitative biomarker assay development for immuno-oncology and targeted therapies.

FDA APPROVED DEVICES

Flagship's technology is used to establish a precision medicine approach and integrates directly into companion diagnostics development.
FEATURED RESEARCH AREAS

Flagship Biosciences speeds drug approval by applying proprietary technology and scientific strategy to pathology-based precision medicine.

IMMUNO-ONCOLOGY COMPANION DIAGNOSTIC APPROACHES

IMMUNO-ONCOLOGY COMPANION DIAGNOSTIC APPROACHES

IMMUNO-ONCOLOGY BIOMARKER MULTIPLEXING

IMMUNO-ONCOLOGY BIOMARKER MULTIPLEXING

IMMUNE CELL MORPHOMETRIC ANALYSIS

IMMUNE CELL MORPHOMETRIC ANALYSIS

MEMBRANE BIOMARKER ANALYSIS

MEMBRANE BIOMARKER ANALYSIS

PD-L1 DIAGNOSTIC APPROACHES

PD-L1 DIAGNOSTIC APPROACHES

IN-SITU HYBRIDIZATION QUANTIFICATION

IN-SITU HYBRIDIZATION QUANTIFICATION

FEATURED TEAM LEADER

Holger Lange, PhD

Dr. Lange is an image analysis expert with 25-plus years experience in all aspects of product development in a wide variety of industries from medical devices to defense, automotive and academia. He has worked for the last 13 years in the medical device industry providing strong leadership and vision in the development of medical imaging systems.

Work With Us

Breadth and depth in people and technology to deliver on any challenge